^SEOUL, Korea, Oct. November 26, 2023 (GLOBE NEWSWIRE) — Novotech (https://novotech-
cro.com/?utm_source=Press+release&utm_medium=Press+release&utm_campaign=All&utm_
term=Contact+Talk+to+an+expert+), the leading one in the Asia Pacific region
based biotech contract research organization (CRO) with worldwide
implementation options, announced today that Dr. Yooni Kim, Vice President
of Clinical Services at Novotech, at the Veeva Korea Summit this week in
Seoul, Korea, gave a keynote speech.
Novotech has been using Veeva’s technology for over a decade
was one of the first adopters of these innovative solutions to improve the
Development of active pharmaceutical ingredients for its biotech customers.
Dr. Kim said:?The customized Novotech Veeva Suite Ecosystem offers
our biotech customers state-of-the-art, optimized processes and an improved
Data transparency, along with advanced study planning and
Predictive functions.”
In her keynote speech, Dr. Kim highlights several key benefits that the
Novotech Veeva platform, including the Vault Suite, to its customers
offers. These benefits include:
* Sharing data from lead trials, sites and investigators across
across different systems
* Shared workflows and reporting – multiple in-platform
Workflows, task assignment, PD escalation, document review/-
creation
* An application means a login to access the
Reporting on TMF, start-up, CTMS, feasibility
* Automatic input of documents at the start of your studies as well as the
Monitoring content into the TMF, in-platform TMF review and
Quality control of documents
* Reuse documents across countries and studies
* Track regulatory and submission milestones
IRB/IEC applications / package review on the platform
* Site Greenlight
* Automated visit tracking
* Track payments
Dr. Kim went on to say that the Vault Clinical Suite is a faster
Enables studies to be carried out and provides cutting-edge findings.
She added:?The platform increases efficiency and ensures a
high quality by promoting data and content sharing,
resulting in greater accuracy in study planning and reporting
She mentioned other advantages, among others:
* Scalability to support harmonized clinical delivery
Studies at Novotech.
* Improved project delivery for our customers, including
Acceleration of start-up times.
* Reporting – real-time, end-user driven and platform-based
Reporting features that are reliable for both Novotech and our customers
Provide data to enable active management of our studies and
to ensure an effective study and portfolio overview.
* A single source for managing feasibility information and
-processes, including the creation of surveys on the platform
as well as dynamic reporting functions.
* Simplified, cost-effective future integrations.
* Enabling clinical systems support services via a
single platform, quick study setup and deployment
a set of accounts and contacts.
Novotech employs more than 3,000 people in 25 countries
34 branches, including in the USA, Greater China, South Korea,
Australia, New Zealand and Europe.
The global CRO offers biotechnology companies a unique and
unparalleled range of early stage contract research services
to late phase in the US and Europe, with a focus on the
Asia Pacific is located where the company has a good reputation in
Related to conducting high-quality accelerated clinical trials
has acquired.
Novotech has been recognized with numerous awards for its industry-leading contributions
Honored with awards including the 2023 CRO Leadership Award and the
Best Cell & Gene Therapy CRO award in 2022 and 2023. About this
In addition, the company was awarded the Asia-Pacific Contract in 2022 and 2023
Research Organization Company of the Year Award. Commitment
of the collaboration company is reflected in the 50 Leading Sites
Partnership agreements it has signed in the last three years.
About Novotech Novotech-CRO.com (https://novotech-
cro.com/?utm_source=Press+release&utm_medium=Press+release&utm_campaign=All&utm_
term=Contact+Talk+to+an+expert+)
Novotech was founded in 1997 and is an international leader
Contract research organization (CRO) in Asia Pacific with global
Implementation options recognized. The company has positioned itself as a clinical CRO
established and has laboratories, phase I facilities, consulting services for
drug development and regulatory expertise. It features
of experience through over 5,000 clinical projects, including clinical
Phase I to IV studies and bioequivalence studies. Novotech employs
Over 3,000 employees in 34 branches worldwide. Novotech has positioned itself as
Partner and ally for small and medium-sized biotech, biopharma and
Pharmaceutical sponsors positioned clinical trials in the Asia-Pacific region
Space, the USA and Europe.
For more information, visit Novotech CRO (https://novotech-
cro.com/?utm_source=Press+release&utm_medium=Press+release&utm_campaign=A)
°